How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

This requires an algorithm: students are taught to stack one number atop another and multiply each digit of the bottom number ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Press’ post set off a firestorm of controversy within the Haskell community, which is small but vocal, and likely felt the ...

Troy Segal is an editor and writer. She has 20+ years of experience covering personal finance, wealth management, and business news. Toby Walters is a financial writer, investor, and lifelong learner.

National security, unlocked. Each Thursday, host Mary Louise Kelly and a team of NPR correspondents discuss the biggest national security news of the week. With decades of reporting from battlefields ...

Your institution does not have access to this book on JSTOR. Try searching on JSTOR for other items related to this book. https://www.jstor.org/stable/10.3366/j ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...